Clinical trial
A Phase 1/2, Multi-Center, Open-Label, Single-Arm Safety, Tolerability, and Efficacy Study of an Auricle and Wedge Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia
NCT06072040 is registered in ClinicalTrials.gov with Auregen Biotherapeutics, SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Multi-Center, Open-Label, Single-Arm Safety, Tolerability, and Efficacy Study of an Auricle and Wedge Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia
- Lead sponsor
- Auregen Biotherapeutics, SA
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- January 26, 2024
- Completion date
- November 14, 2025
- Enrollment
- 3 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
microtia